Medicine & Pharmaceuticals News
Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
This development, which includes the acquisition of state-of-the-art diagnostic equipment and an increase in specialized staffing, is designed to provide more accessible and timely answers for those grieving the loss of a loved one. The expansion directly addresses the community's growing need for Private Autopsies in St Louis , which can offer crucial information when official autopsies are not performed. For families facing unanswered questions surrounding a cause of death, these services provide an essential path toward understanding, closure, and peace of mind. The enhanced capacity allows Postmortem Pathology to reduce wait times and deliver comprehensive reports more efficiently. This investment strengthens the organization's ability to support families during a profoundly difficult time. The new equipment enhances diagnostic accuracy, while additional board-certified pathologists and support staff ensure that each case receives meticulous and compassionate attention. "When a family loses someone, the search for answers can be an overwhelming part of the grieving process," said Dan Lingamfelter, Lead Pathologist at Postmortem Pathology. "Our expansion is driven by a commitment to the St. Louis community. By increasing our capacity and technological capabilities, we can provide more families with the definitive, compassionate, and timely clarity they deserve." The private autopsy services offered by Postmortem Pathology are independent of coroner or medical examiner systems, giving families a dedicated option for investigating medical conditions, confirming clinical diagnoses, and addressing concerns about the circumstances of a death. About Postmortem Pathology Postmortem Pathology is a leading provider of Private Autopsy Service and postmortem examination services. Staffed by a team of board-certified pathologists, the organization is dedicated to delivering accurate, thorough, and compassionate diagnostic services to families seeking understanding and closure after the loss of a loved one.
Pharmacy CCM & RPM Program Implementation With Physician Partnership Announced
Simon Faynboym Recognized For Leadership And Measurable Mental Health Care Improvements With 2025 Global Recognition Award
Creative Biolabs Strengthens Solid Tumor ADC Strategy with Three High-Value Target Additions
- November 24, 2025Medicine & Pharmaceuticals
CD Bioparticles Launches New Portfilio of Custom Services to Advance Beads-Based Cell Isolation
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the launch of its comprehensive custom services for Beads-Based Cell Isolation utilizing Magnetic Activated Cell Sorting (MACS) technology. These new offerings will help scientists streamline research and clinical workflows, as the key parameters such as purity, viability and recovery can be provided according to their specific requirements. MACS is a highly specific and rapid cell sorting technology based on magnetic particles that is widely used in immunology, stem cell research, oncology and clinical medicine. It employs antibody-conjugated magnetic particles to capture antigens on the surfaces of target cells, causing them to adhere to the sidewalls of a magnetic field. This separates unlabelled cells without bound magnetic particles from the cell suspension. To meet the growing needs of scientists, CD Bioparticles now offers customized antibody-conjugated magnetic nanoparticles and cell sorting validation services. The diameter of the magnetic nanoparticles and the antibody conjugation method can both be tailored to specific requirements. For cell sorting validation, CD Bioparticles can provide relevant data on key parameters such as purity, viability and recovery rate. The magnetic particles supplied by CD Bioparticles are engineered for optimal performance, ensuring minimal disruption to cells. They offer significant advantages in various biological fields, primarily due to their superior handling and performance characteristics. Their nanoscale size and dextran coating ensure excellent biocompatibility and minimal impact on cell function and viability, while also contributing to low non-specific binding. These particles are designed for simple and efficient separation, eliminating the need for expensive specialist equipment. Furthermore, they are easy to conjugate and, as they are suitable for high-temperature sterilisation prior to conjugation, they are better suited to aseptic control. This combination of features results in high cell purity and recovery. Their broad utility makes them ideal for a range of applications, including stem cell and cancer research, immunology, diagnostics, clinical applications, drug development and quality control in cell manufacturing. CD Bioparticles' custom services provide researchers with critical flexibility. The company specializes in the synthesis of basic magnetic nanoparticles in a range of diameters, including 50 nm and greater than 200 nm, to perfectly match clients' experimental needs. For the 50 nm particles, separation requires a dedicated sorting column and matching magnetic frame, whereas particles with a diameter greater than 200 nm can be separated using an ordinary magnet without a sorting column. Additionally, CD Bioparticles provides antibody conjugation upon request, enabling researchers to select the desired coupling method, including chemical and biological conjugation based on streptavidin (SA)-biotin. CD Bioparticles also offers SA magnetic nanoparticles and biotinylated antibodies individually for flexible ratio adjustment. Furthermore, clients can request cell-sorting validation, for which CD Bioparticles can provide comprehensive data on the positive rate, viability and recovery for both the flow-through and retained fractions. To know more information about the new services, or to contact the CD Bioparticles team for a consultation, quote, or proposal, please visit https://www.cd-bioparticles.com/s/Beads-Based-Cell-Isolation_28.html . About CD Bioparticles CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.
- November 24, 2025Medicine & Pharmaceuticals
STEMart Launches Comprehensive In Vitro Chromosome Aberration Test Service to Bolster Medical Device Safety and Compliance
STEMart, a US-based provider of comprehensive services for all phases of medical device development, has announced the launch of its In Vitro Chromosome Aberration Test service. This critical genetic toxicology assessment is essential for manufacturers seeking global regulatory clearance by evaluating the clastogenic potential of medical devices and materials. Genotoxicity testing involves evaluating the risk that test substances will induce gene mutations or chromosomal damage, using multiple in vitro and in vivo bacterial and mammalian cell testing systems. As a specialist in the medical device services sector, STEMart offers a range of diverse genotoxicity and biocompatibility testing solutions, including the Bacterial Reverse Mutation Test (Ames) and the In Vitro Mouse Lymphoma Assay TK. These solutions are designed to meet the varied testing needs and requirements of clients. STEMart strictly adheres to OECD guidelines revised for the medical device sector and conducts testing under Good Laboratory Practice (GLP) conditions. The In Vitro Chromosome Aberration Test is performed according to the rigorous standards of OECD Guideline for the Testing of Chemicals, Test No. 473, and is a core requirement within the ISO 10993-3 biocompatibility standard. The aim of this assay is to identify chromosomal structural abnormalities, including deletions, breaks and exchanges, that could potentially be induced when extracts from medical devices come into contact with mammalian cells. The results of this test provide critical data for assessing the genetic safety of new products. STEMart now offers in vitro chromosome aberration testing to evaluate the ability of medical devices to cause structural aberrations in mammalian cell chromosomes. This testing can be conducted under GLP (Good Laboratory Practice) or non-GLP conditions. The assay can be performed using either human pulmonary alveolar epithelial cells (HPBLs) or established cell lines, such as Chinese hamster ovary (CHO) cells. This test is applicable to medical devices intended for permanent or long-term patient contact, or for contact with blood. The testing can be conducted in two ways, including the short-term exposure (4 hours) with metabolic activation (S9) conditions, or long-term exposure (21 or 24 hours) without S9 conditions. Manufacturers can use this approach to comprehensively evaluate potential mutagenic effects. In addition, GLP-compliant and non-GLP options are available to meet diverse client requirements. STEMart also provides the final report that includes the detailed methodology, the raw data and expert interpretation to clients, supporting manufacturers to meet the regulatory goals and minimize the compliance risks. STEMart offers the chromosomal aberration test to evaluate whether a medical device compound could cause chromosomal abnormalities. To learn more about these services and other medical device testing solutions, or to consult with the experts at STEMart, please visit https://www.ste-mart.com/in-vitro-chromosome-aberration-test.htm . About STEMart STEMart is an industry-leading eCommerce platform incorporated with an extensive global footprint and a broad portfolio of more than 10,000 products. It aims to provide better lab materials, medical instruments and consumables, excellent technologies, and high-quality services to global customers in the fields of science, technology, and engineering, from the discovery stage upward to the manufacturing process. STEMart is dedicated to enhancing research and biotech production with simpler and safer protocols to access better health worldwide.
- November 24, 2025Medicine & Pharmaceuticals
Creative Diagnostics Launches Comprehensive Suite of HSV Animal Model Services to Support Antiviral Research
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its Herpes Simplex Virus (HSV) Animal Model services to the research community. These HSV animal models can provide scientists with critical in vivo tools to investigate the complex biology, pathogenesis, and immune response associated with HSV-1 and HSV-2, which will help to accelerate the development of new therapeutics and vaccines. HSV is primarily classified into two types, HSV-1 and HSV-2. HSV-1 and HSV-2 are among the most common human viruses globally. HSV-1 typically infects the mucosal epithelium of the oral cavity or eyes, causing cold sores or herpetic stromal keratitis (HSK), while HSV-2 is the primary cause of genital herpes. HSK is a form of corneal inflammation that can lead to blindness, and it originates from a primary HSV-1 infection followed by viral latency in sensory and autonomic ganglia. Most cases result from reactivation of the latent infection. Animal models are crucial for investigating HSK pathogenesis and therapeutic approaches. Mice and rabbits are the most commonly used animal models for studying HSV-1 latency, reactivation and recurrence. As a leading service provider in infectious disease research, Creative Diagnostics is dedicated to advancing the understanding of the herpes simplex virus by developing reliable animal models. The company's mission is to provide clients with cutting-edge tools and innovative methodologies to explore the complex biological mechanisms of HSV, including its molecular structure, pathogenic pathways, disease progression and immune defence systems. An ideal HSV animal model must possess key characteristics such as an immune system identical to that of humans, reproductive tract anatomy consistent with humans, and cellular components that interact with HSV immune evasion mechanisms corresponding to human cells. Creative Diagnostics' research team has successfully developed a series of animal models specifically engineered for HSV research. These include the HSV vaginal infection mouse model, the HSV brain infection mouse model, the HSV-induced rabbit keratitis model and the HSV-induced guinea pig skin injury model. Each model is meticulously designed to balance unique advantages with inherent limitations. Leveraging an advanced animal model technology platform, Creative Diagnostics offers multiple HSV latent infection inoculation protocols, including intranasal, digital, corneal scratch, tail vein, and tooth extraction inoculations. Models can be customized to meet specific research requirements by adjusting key experimental parameters such as the animal species, age, genotype, the route of infection, the viral serotype, strain and dose. Creative Diagnostics offers comprehensive services to support enterovirus animal model research. These services include study design and implementation, pathological analysis, immunological response profiling, in vivo pharmacokinetic studies and efficacy-toxicity assessments. Researchers can use these services to investigate acute, latent and recurrent HSV-1 and HSV-2 diseases, explore the precise mechanisms of HSV-mediated pathologies and develop and evaluate therapeutic agents and vaccines against HSV infection. Creative Diagnostics is committed to empowering scientists to pioneer new approaches to HSV prevention, diagnosis and therapeutic interventions. For more information on these models or related innovative solutions for preclinical research involving infectious diseases, please visit https://antiviral.creative-diagnostics.com/hsv-animal-model.html . About Creative Diagnostics Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
- November 20, 2025Medicine & Pharmaceuticals
Comstock Health Offers Free Open Enrollment Policy Reviews for Utah Residents
Salt Lake City, UT — Comstock Health Insurance, a leading health insurance brokerage serving thousands of clients across Utah, has announced that founder and licensed agent Christopher Comstock will offer free health insurance policy reviews during the 2026 Open Enrollment period. This initiative is part of ComstockHealth’s ongoing commitment to improving client support and ensuring individuals, families, and small businesses have access to the best coverage options available. With offices in both Salt Lake City and Park City Utah, ComstockHealth continues to expand its presence and resources to better meet increased demand during the busy enrollment season. “We’re proud to serve the Salt Lake and Park City Utah communities and want to be fully accessible during open enrollment,” said Comstock. “With so many insurance options, price increases, and recent industry changes, reviewing your policy with a professional can make a significant difference.” ComstockHealth has earned a strong reputation for helping clients navigate complex health insurance decisions. Known for personalized service and award-winning support—including recognition as Insurance Company of the Year—the firm has helped thousands of Utah residents secure tailored, cost-effective health insurance plans. By offering free policy reviews, Comstock Health aims to help clients: Understand how upcoming insurance changes may affect their coverage Compare plan options based on their health needs and financial goals Identify cost-saving opportunities and available subsidies Select plans that provide strong protection at a reasonable premium Comstock notes that the health insurance landscape has evolved significantly: “Competition in the small-business and individual markets has opened new opportunities that didn’t exist even five years ago. This makes it even more important to review coverage during open enrollment.” The complimentary service is available to small business owners, families, individuals, and anyone needing expert health insurance guidance. For more information or to schedule a free policy review, visit: comstockhealth.com
- November 15, 2025Medicine & Pharmaceuticals
Global Immigration Partners Announces Updated Insights for E-2 Visa Investors Exploring U.S. Green Card Options
Global Immigration Partners Announces Updated Insights for E-2 Visa Investors Exploring U.S. Green Card Options Global Immigration Partners PLLC, a premier U.S. immigration law firm specializing in investor and business immigration, today released a new advisory for international entrepreneurs seeking clarity on a widely debated topic: Can the E-2 Treaty Investor Visa ultimately lead to a U.S. Green Card? The firm confirms that while the E-2 Visa is a non-immigrant category and does not directly allow for permanent residency, many E-2 investors can and do transition to Green Cards by leveraging strategically selected, compliant immigration pathways. E-2 Visa to Green Card: Expanded Legal Pathways for Investors Global Immigration Partners highlights several U.S. immigration strategies commonly used by E-2 visa holders pursuing permanent residency: 1. EB-5 Immigrant Investor Green Card E-2 investors may be able to restructure or expand their business investment to meet EB-5 criteria, including: Legal investment of $800,000 to $1,050,000 Creation of 10 full-time U.S. jobs Capital at risk and traceable lawful investment funds The firm notes that many E-2 enterprises can be adapted to EB-5 compliance through detailed planning. 2. EB-1C Multinational Manager or Executive Category Investors managing multinational operations may transition to a permanent residency category designed for senior executives who oversee global business entities. 3. Employment-Based EB-2 or EB-3 Sponsorship E-2 visa holders employed by U.S. companies—whether their own or another entity—may qualify for employer-sponsored PERM-based Green Cards. 4. Family- or Marriage-Based Adjustment of Status Eligible E-2 holders with qualifying U.S. family relationships may access permanent residency through established family immigration channels. Expert Commentary from Global Immigration Partners “ Despite its temporary classification, the E-2 Visa can serve as a powerful foundation for long-term immigration planning, ” said Alexander Jovy, co-managing Partner at Global Immigration Partners PLLC . “ With a structured approach—whether through EB-5 investment, multinational business expansion, or employment-based strategies—investors can pursue a stable path toward permanent U.S. residency. ” Global Immigration Partners ’ Strategic Approach for E-2 Investors The firm is recognized for its ability to convert complex investor scenarios into actionable immigration strategies. Key advantages include: Highly specialized teams in EB-5, E-2, EB-1C, and employment-based Green Cards Proven experience restructuring E-2 business models for EB-5 eligibility A data-driven, compliance-focused legal approach Support for investors across North America, the Middle East, Europe, Africa, and Asia Global Immigration Partners continues to advise entrepreneurs, innovators, and multinational business owners on achieving long-term U.S. immigration outcomes. About Global Immigration Partners PLLC Global Immigration Partners (https://globalimmigration.com/ ) is a leading U.S. immigration law firm based in Washington, D.C., providing expert legal services in investor visas, business immigration, and permanent residency solutions. The firm is known for its personalized strategies, global reach, and high approval rate in investor-based categories. Media Contact Global Immigration Partners PLLC Website: https://globalimmigration.com/ Email: [email protected] Phone: (+1) 267-507-6078
- November 14, 2025Medicine & Pharmaceuticals
Creative Biolabs Unveils Its "All-in-One" Platform Driving Antibody and Protein Engineering at PEGS Europe
In the vibrant field of biopharmaceutical innovation, there is always something on the horizon. The Creative Biolabs team showcased a new series of updates in antibody discovery, production, and optimization and was prepared to continue discussions on hot topics in CDMO services. Antibody CDMO—The "All-in-One Workshop" of Antibody Manufacturing When an antibody drug transitions from concept to clinic, what concerns developers the most? Not a lack of creativity, but a loss of control in execution. Creative Biolabs' antibody CDMO solutions are designed to help overcome that bottleneck. It's an "all-in-one workshop" that takes you from DNA to cGMP, allowing you to keep antibody R&D from fragmented outsourcing. An expert from the company remarked at the event, "We are seeing clients wanting more integrated and responsive systems from manufacturers. It's more than just producing contracts; it's about co-creation. We are trying to build safe and effective expressways for all innovative molecules." Covering scales from 2 L to 2,000 L, supporting multiple formats (mAbs, BsAbs, ADCs), and allowing partners to complete all the developmental stages within one streamlined logical sequence are all aspects of integrated systems for co-creation. Recombinant Antibody Engineering —Making Proteins Smarter The recombinant antibody production and engineering module allows antibodies to be re-engineered like building blocks—whether humanized, fragmented, single domain, or bispecific, all variants are designed with biological precision. During a talk, an expert stated, "Traditional recombinant production is just manufacturing. What we do is molecular craftsmanship, and we can predict which residues impact affinity and which mutations enhance stability. These 'fine-tunings' will improve the odds of success throughout the development process." OmicsAb™ Platform—A High-Throughput Engine That Bends Time The OmicsAb™ high-throughput antibody production platform was one of the most "time-defying" highlights at PEGS Europe. It breaks the limits of traditional 96-well expression systems and supports fully automated cloning, expression, and purification. "Within days, we express and purify hundreds of candidate antibodies. This is a game-changer! Screening is no longer a slow process. It is a precision and efficiency race now." The OmicsAb platform works with different host systems, including CHO and HEK293, which allows biopharma developers to scale their cross-system biopharma testing. This versatility boosts the rapid early-stage decision-making, ultimately streamlining the system to meet the biopharmaceutical innovation pace. "PEGS Europe is not just an exhibition—it's a mirror. It reflects the challenges of the industry while also revealing our own potential. Our mission is to make complex technologies controllable, reproducible, and scalable." About Creative Biolabs Creative Biolabs continues to focus on process development of bispecific antibodies, Fc-fusion proteins, and ADCs, along with the combination of AI-driven design and high-throughput screening to explore new frontiers in the manufacturing of next-gen biotherapeutics.
- November 14, 2025Medicine & Pharmaceuticals
Medical Drug Testing Kits & Services: Oral Fluid Screening Products Announced
12 Panel Now has announced the official launch of its oral fluid screening product line to meet a growing demand for reliable drug testing from treatment centers and healthcare providers nationwide. More information is available at https://12panelnow.com/product-category/oral-swabs/ The company's latest product line features both Pen Style and Oral Swab formats designed for various testing needs and environments, with options spanning from 3-panel basic screenings through 14-panel comprehensive tests. The Oral Pen™ has been recognized as the world's first saliva drug test with integrated test strips that allow administrators to view results directly on the collection device, eliminating the need for separate testing components. These non-invasive devices collect saliva samples from inside the cheek, which can then be immediately inserted into the testing panel rather than being transferred between locations. Each test detects multiple substances simultaneously, including amphetamines, barbiturates, benzodiazepines, buprenorphine, cocaine, fentanyl, methamphetamine, opiates, oxycodone, THC, and alcohol, with specialized configurations available for emerging substances like tianeptine (ZAZA) and xylazine. All products are manufactured under the company's Serenity brand and include both FDA-approved and CLIA-waived testing options, with results that can be photocopied for permanent record-keeping purposes. "We built this company on the belief that accurate drug testing should be available to everyone who needs it, not just those who can afford it," said a company representative. "Our oral fluid screening products reflect eight years of listening to our customers and understanding what works in real-world testing situations." Founded by individuals with personal connections to recovery, 12 Panel Now serves more than 20,000 active customers monthly. What started as an effort to help friends in recovery access affordable testing options has evolved into a national supplier trusted by major institutions. The customer base includes the U.S. Army, rehabilitation programs, correctional facilities, probation departments, treatment centers, healthcare providers, and medical distributors. Through its manufacturing division, Slash Medical, the company provides private labeling, OEM manufacturing, and large-scale distribution. To learn more about 12 Panel Now and its oral fluid screening products, visit the official company website at https://12panelnow.com/
- November 11, 2025Medicine & Pharmaceuticals
Hair of Istanbul Sets Global Standard for Discreet, High-Profile Hair Transplants Among Celebrities
Hair of Istanbul (HOI), one of the world’s most recognized names in hair restoration, continues to earn its reputation as a premier destination for privacy-driven and high-precision hair transplant procedures. As global demand for advanced follicular unit extraction (FUE) techniques rises, the clinic remains the trusted choice for public figures, executives, and celebrities who seek transformative results with total confidentiality. Where Precision Meets Privacy In the entertainment and sports industries, appearance and confidence often directly influence careers. Hair of Istanbul has become a leading name among those who value discretion as much as artistry. While many high-profile individuals have undergone hair restoration, only a few have publicly discussed their procedures. Hair of Istanbul’s approach has made it a preferred option within this elite circle — offering state-of-the-art medical techniques, personalized planning, and a guarantee of privacy. The clinic’s policy is straightforward: it never reveals client names or details, allowing outcomes to speak for themselves while safeguarding client confidentiality. This privacy-first philosophy has positioned HOI as a clinic that celebrities trust implicitly, ensuring that personal enhancement never compromises personal boundaries. The Global Rise of Celebrity Hair Restoration Over the past decade, hair transplants have shifted from a niche cosmetic procedure to a mainstream confidence investment. Public figures such as athletes, actors, and musicians have normalized the conversation around hair restoration, contributing to a broader cultural acceptance of aesthetic medicine. While many destinations offer transplant services, Turkey remains the leading hub for world-class outcomes. Hair of Istanbul stands at the forefront of this success, combining advanced surgical techniques, medical innovation, and an international patient-care model that meets the highest clinical standards. Why Celebrities Choose Istanbul Three main factors keep Istanbul — and Hair of Istanbul specifically — at the top of global patient preference lists: Expertise Density: Turkey’s concentration of experienced surgeons enables consistency and precision unmatched by many international markets. Comprehensive Journey: Hair of Istanbul offers an end-to-end experience, from private airport transfers and premium accommodation to attentive aftercare. Discretion and Trust: For high-profile clients, the clinic’s commitment to privacy and individualized care makes it a sanctuary for personal transformation. In addition to Istanbul, HOI has expanded services to accommodate international clients seeking enhanced privacy and convenience in locations such as Dubai, reflecting its growing global demand. Commitment to Excellence and Safety Every procedure at Hair of Istanbul is customized to the individual’s hair type, facial structure, and goals. The clinic’s surgical teams follow stringent medical protocols and employ cutting-edge FUE and DHI techniques to ensure natural-looking results and minimal downtime. Transparency, surgeon accountability, and post-treatment support remain central to the clinic’s patient care philosophy — distinguishing HOI as a leader in both artistry and medical ethics. About Hair of Istanbul (HOI) Hair of Istanbul is a globally recognized hair transplant and restoration clinic headquartered in Istanbul, Turkey. Established with a mission to combine medical excellence, innovation, and confidentiality, HOI specializes in FUE and DHI techniques performed by expert surgeons. The clinic’s privacy-first approach and exceptional results have made it a trusted destination for international patients, including public figures, business leaders, and celebrities seeking the highest standards in hair restoration. For more information on Hair of Istanbul’s services and global patient programs, visit the official website.
- November 10, 2025Medicine & Pharmaceuticals
Chronic Care Management Program: CCM & RPM Healthcare Consulting Services Expand
As part of its expanded consulting services, the team assists healthcare providers in establishing Medicare-compliant Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) programs. The service offering covers workflow design, compliance documentation, staff training, and technical onboarding. More information is available at https://ccmrpmhelp.com CCM RPM Help's consultants work directly with healthcare teams to optimize internal workflows, configure electronic health record (EHR) systems, and ensure billing accuracy across all phases of care coordination implementation. This structured approach enables healthcare organizations to improve chronic disease outcomes while generating sustainable, recurring revenue through eligible reimbursements. CCM and RPM programs have been shown to reduce hospital readmissions, lower overall healthcare expenditures, and increase patient engagement. In addition to supporting clinical performance, such programs contribute to operational efficiency by streamlining communication, automating follow-ups, and maximizing team productivity. CCM RPM Help's consulting model is designed to address operational gaps common among practices and pharmacies, particularly those seeking to offer care between appointments but lacking the resources or technical knowledge to manage Medicare's administrative and billing requirements. The consulting team provides step-by-step guidance on CPT codes, documentation standards, and system integration, customizing the rollout to align with each organization's existing processes. "Our priority is ensuring that every component — from documentation to reimbursement — is aligned from the beginning," said a company spokesperson. "This enables providers to deliver continuous care without disruption, while also improving financial performance." Following implementation, the firm continues to offer performance monitoring and process refinement to support long-term success. About CCM RPM Help CCM RPM Help is a healthcare consulting firm founded by professionals with extensive experience in clinical operations, technology, and practice management. The company specializes in supporting healthcare providers and pharmacies with the implementation of Medicare-compliant care coordination programs. A client said, "We've seen better care and new revenue without adding staff." For further details or to schedule an online call, visit https://ccmrpmhelp.com
- November 3, 2025Medicine & Pharmaceuticals
New York Multi-Language Medical Translation & Interpretation: Services Expand
Gateway Languages has announced an expansion of its multilingual services for healthcare providers. The company highlights the role of professional human interpreters in patient safety and diagnostic accuracy, addressing risks associated with relying on artificial intelligence (AI) for communication in clinical settings. More information is available at https://gatewaylanguages.com Relying on AI for medical translation can present challenges to patient care. Studies indicate that machine translation systems may produce significant errors, particularly with complex medical information or in languages with fewer digital resources. At the same time, a study in the Annals of Emergency Medicine found that encounters using ad hoc interpreters, such as family members, had a significantly higher rate of errors with potential clinical consequences compared to those using professional interpreters. To address these challenges, Gateway Languages offers a range of accessible, multi-modal services. Healthcare providers can connect with qualified professionals through On-site (OSI), Over-the-Phone (OPI), and Video Remote (VRI) interpretation. The services are available around the clock in over 500 languages, providing timely access for medical staff. "Working with a professional language service can help facilities reduce clinical risks, such as misdiagnoses and medication errors that stem from communication barriers," explains a spokesperson. "Furthermore, this approach supports compliance with federal and state language access mandates, which reduces legal risks for the facility and improves patient safety." A significant distinction from automated systems is the human element of cultural brokerage; the nuances where artificial intelligence often falls short, adds the representative. Interpreters can act as cultural liaisons, helping to explain cultural beliefs or practices that may influence a patient's health decisions. This nuanced communication builds trust across the language barrier and can contribute to better health outcomes. Gateway Languages uphold the highest standards to ensure doctors and other medical professionals can use their services with confidence. The company employs state or nationally certified professionals with medical experience to maintain a standard of accuracy and understanding of complex terminology. All services are HIPAA compliant, with the company operating under Business Associate Agreements (BAAs). They also adhere to regulatory standards, including ACA Section 1557 and Title VI of the Civil Rights Act. Gateway Languages provides support for small to mid-sized medical facilities, including hospitals, urgent care clinics, and specialized treatment centers. To learn more about improving patient communication through language services, visit https://www.gatewaylanguages.com
- November 2, 2025Medicine & Pharmaceuticals
Duopharma Biotech showcases halal pharmaceutical production to SMIIC delegation
Kuala Lumpur, 16 October 2025 — Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) recently welcomed approximately 30 delegates from the Standards and Metrology Institute for Islamic Countries (“SMIIC”) at its Klang manufacturing facility, in a technical visit organised by the Department of Standards Malaysia (“DSM”) in conjunction with the 14th SMIIC Technical Committee Week 2025, hosted in Kuala Lumpur from 22 to 26 September. SMIIC is an institute under the Organization of Islamic Cooperation (“OIC”), with a mission to establish uniformity in standardisation, metrology and accreditation activities to facilitate trade and support sustainable economic growth, consumer welfare, and environment and innovation promotion for Member States. During the visit, the delegates, comprising technical experts from SMIIC member countries, received an overview of best practices within Malaysia’s halal pharmaceutical industry, facilitated by Duopharma Biotech’s Halal & Government Relations Department. The Company’s manufacturing facility in Klang is a Good Manufacturing Practices (“GMP”)-certified plant focusing on advanced pharmaceutical technologies. It manufactures halal pharmaceutical products comprising a wide array of tablets, capsules, syrups, oral antibiotic creams, solutions for haemodialysis and sterile irrigation, injectables, dental cartridges and eyedrops, for export and domestic markets. Wan Amir-Jeffery Wan Abdul Majid, Group Chief Executive Officer of Duopharma Biotech Berhad, commented, “It is a great honour to showcase Duopharma Biotech’s manufacturing facilities to the SMIIC delegation, enabling them to witness how we practise our holistic “Halal Built-In, Not Tested For” principle. As a global pioneer in the halal pharmaceutical sector, working closely under the leadership of the Department of Islamic Development Malaysia (“JAKIM”), DSM and the Halal Development Corporation (“HDC”), we have made significant progress in international outreach to growing our markets. With the halal pharmaceuticals sector projected to reach USD5.9 billion in value by 2030, our goal is to provide safe, effective, high-quality halal-certified products that broaden healthcare choices for patients. At the same time, the scalability of halal requires education, as many international partners are only beginning to understand its value. With Malaysia’s maturity and proven track record, we are well-positioned to guide this journey, and by sharing our progress from food to pharmaceuticals, we can build global trust and harmonise halal standards.” “We are delighted to have the opportunity to visit Duopharma Biotech’s manufacturing plant. Malaysian government institutions like DSM and JAKIM have established a strong halal ecosystem supported by regulatory and industry collaboration, and SMIIC is keen to observe how these practices are implemented in halal manufacturing. We were pleased to learn how a key pharmaceutical player engages in collaboration with regulatory bodies during early product development, substituting prohibited ingredients, adjusting production lines, and pioneering new methods of quality assurance to ensure every ingredient and production process aligns with halal requirements. It is further reassuring to see the integration of digital technology such as blockchain, IoT and AI in every stage of production and logistics to improve traceability and transparency. I look forward to seeing these processes expanded to more SMIIC member countries,” added Dr. Mohammed Ali Alsheikh, SMIIC Technical Assistance, TC 16 Halal Medical Issues. A Global Leader in Halal Pharmaceuticals Duopharma Biotech has been a global pioneer of halal pharmaceutical manufacturing for close to three decades, beginning in 1998 when halal was integrated with GMP requirements for all production lines and manufacturing processes. All its manufacturing facilities are fully halal-compliant, adhering to the Malaysian Standard MS 2424:2019 for Halal pharmaceuticals and the OIC standard SMIIC 50-1. The Company first obtained Halal certification from JAKIM in 1999 for its Consumer Healthcare brands such as CHAMPS®️, FLAVETTES®️, PROVITON®️ and NATURALLE, followed by becoming the first pharmaceutical manufacturer to receive halal certification for prescription medicines in 2017, the first Halal certification for a cancer treatment product in 2022, and halal certification for a treatment targeting anaemia associated with chronic renal failure in 2025. To further grow the halal pharmaceuticals sector, Duopharma Biotech has organised the Halal Pharmaceuticals Symposium since 2016, gathering international experts, industry leaders and standards and regulatory agencies to advance the integration of Halal pharmaceuticals into the global healthcare system. At the symposium, participants exchange ideas and opinions, share best practices and successes and collaborate to solve challenges faced by the halal pharmaceutical industry. Duopharma Biotech is a member of HDC’s Sectoral Working Group tasked with reviewing and monitoring the implementation of identified initiatives, guided by the Sectoral Roadmap for Halal Pharmaceuticals to drive the industry’s growth. A Strategic Approach to Medicine Access Duopharma Biotech takes a holistic approach to ensuring that all patients have access to the medicines they need. Beyond a focus on halal pharmaceuticals, it is imperative to ensure that the supply of critical medicines is robust and reliable in order to ensure that the needs of patients are met. Aligned with the Government’s Medicine Security strategy to ensure a sustainable supply of essential medications, the Company has made a strategic commitment to shoring up its ability to supply Recombinant Human Insulin (“RHI”) for patients with diabetes in Malaysia since 2016. Since then, Duopharma Biotech, together with its long-term partner company Biocon, has established itself as the primary RHI supplier in Malaysia, via production at Biocon’s manufacturing facility in Johor and bolstered by multiple sources of supply globally. Leveraging our recent success in obtaining Halal certification for a biosimilar erythropoietin product used for the treatment of anaemia in chronic kidney disease patients, Duopharma Biotech is working closely with Biocon to extend this expertise to their RHI portfolio, advancing Halal certification efforts and reinforcing global confidence in Halal-compliant biopharmaceuticals.
ALL NEWS
- Dog Bite Laws Continues Tradition and Hosts Annual “The Warming Project” Chicagoland Community Event
- Clip Launches Guest-Powered Wedding Video Service, Filmed by Guests and Edited by Pros
- Dog Bite Laws Continues Tradition and Hosts Annual “The Warming Project” Chicagoland Community Event
- ServiceNow Wins Best Use of AI for Accessibility at the Netty Awards
- Spread Holiday Cheer at Emerald Jewelers, Best Jewelry Store in Salem, NH!
- Mark of the Beast & the Role of Technology: Christian Prophecy Analysis Released
- Coastal Moving Services Launches Transparent Long-Distance Moving Assistance To Protect Consumers Nationwide
- Harwoods Group Announces Exclusive Event in Audi Portsmouth, Including Test Drive of the New Audi e-tron GT
- The Natural Wood Floor Unveils First Look At Continuous Versaille Oak Parquet Woodblock
- IRI Spotlighted Again in the Big Data Market
- Bamboo Boutique Introduces Initia Diode Laser Technology to Edinburgh, Setting a New Standard for Pain-Reduced Hair Removal
- Rise Men's Health Publishes New Article On The Effects Of Low Testosterone
- Rollney Singapore Unveils Innovative Fully Robotic Soft Serve Vending Machine
- Eastern Health Cluster Honored With 2025 Global Recognition Award For Leadership, Service Delivery, And Research Excellence
- Incorpify AI Wins 2025 Global Recognition Award for Changing Business Formation Through Artificial Intelligence
- Incorpify AI Honored with 2025 Global Recognition Award for Transforming Business Incorporation
- Martha Vieira Wins a 2025 Global Recognition Award for Advancing Lean Construction in Civil Design with Measurable Results
- P·TAL Brings India’s Only UNESCO-Listed Craft to American Kitchens: The Holiday Gift That Reimagines “Clean Cooking”
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS